Page 34 - Development Activities News Today

AMENDED AND RESTATED STATEMENT OF RESERVES DATA AND OTHER OIL AND GAS INFORMATION For the Year Ended December 31, 2023 March 25,...

/PRNewswire/ -- The "Europe Nucleic Acid Therapeutics CDMO Market: Analysis and Forecast, 2023-2033" report has been added to ResearchAndMarkets.coms offering....

Dublin, Feb. 28, 2024 (GLOBE NEWSWIRE) -- The

/PRNewswire/ -- The "Asia-Pacific Low Carbon Aluminum Market: Analysis and Forecast, 2022-2031" report has been added to ResearchAndMarkets.coms offering. The...

Net Loss: Increased to $116.4 million in Q4 and $444.0 million for the full year, reflecting investment in commercial and development activities. Research and Development: R&D expenses rose to $87.5 million in Q4, driven by manufacturing and clinical trial costs. Selling, General and Administrative Expenses: Increased to $29.9 million in Q4, supporting business growth and Proleukin integration.

The Hyderabad Bench of Income Tax Appellate Tribunal (ITAT) has held that the notion of earning 90% profit is unimaginable and is contractual loot under the guise of alleged development activities.The...

Dublin, Feb. 22, 2024 (GLOBE NEWSWIRE) -- The

/PRNewswire/ -- EOG Resources, Inc. (EOG) today reported fourth quarter and full-year 2023 results. The attached supplemental financial tables and schedules...

/PRNewswire/ -- The "Calcium Gluconate - Global Strategic Business Report" report has been added to ResearchAndMarkets.coms offering. Global Calcium Gluconate...

EOG Resources, Inc. (EOG) today reported fourth quarter and full-year 2023 results. The attached supplemental financial tables and schedules for the reconciliation of non-GAAP measures to GAAP measures and related definitions, along with a related...